FLT3 and acute lymphoblastic leukemia: Furthermore, several targeted therapeutic agents have been developed based on the intrinsic biological features of ETP‐ALL, including JAK inhibitors, hypomethylating agents (HMAs), histone deacetylase inhibitors, FLT3 inhibitors, CD33‐conjugated antibodies, and CD38 monoclonal antibodies [13].